We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
151
Adicet Bio
ACET
$77.6M
$1.29M 0.1%
7,847
-596
-7% -$121K
ANEB
152
DELISTED
Anebulo Pharmaceuticals
ANEB
$1.2M 0.1%
+174,811
New +$1.3M
ASND icon
153
CALL
Ascendis Pharma A/S
ASND
$16.5B
$1.13M 0.09%
8,600
-42,100
-83% -$5.61M
ATXS
154
DELISTED
Astria Therapeutics
ATXS
$1.12M 0.09%
88,716
-53,450
-38% -$694K
BCLI
155
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.11M 0.09%
19,547
– –
QNCX icon
156
Quince Therapeutics
QNCX
$21.5M
$1.09M 0.09%
+103
New +$864K
EYPT icon
157
EyePoint Inc
EYPT
$999M
$1.08M 0.09%
120,135
– –
MRUS
158
DELISTED
Merus
MRUS
$1.08M 0.09%
51,223
-60,000
-54% -$1.33M
RGLS
159
DELISTED
Regulus Therapeutics
RGLS
$1.01M 0.08%
124,599
– –
KRRO icon
160
PUT
Korro Bio
KRRO
$145M
$1M 0.08%
2,016
– –
TPST icon
161
Tempest Therapeutics
TPST
$14.3M
$1M 0.08%
6,913
– –
PBLA
162
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$976K 0.08%
14
– –
ONCT
163
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$950K 0.08%
10,010
-13,006
-57% -$1.54M
ATNX
164
DELISTED
Athenex, Inc. Common Stock
ATNX
$923K 0.07%
+10,000
New +$909K
HYFT
165
MindWalk Holdings
HYFT
$60.7M
$903K 0.07%
150,000
– –
PSTX
166
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$861K 0.07%
85,837
– –
AFMD
167
DELISTED
Affimed
AFMD
$792K 0.06%
+9,310
New +$849K
BLSA
168
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$791K 0.06%
75,100
– –
GRI
169
GRI Bio
GRI
$2.6M
– –
0
– –
MITO
170
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$761K 0.06%
488,014
-300,000
-38% -$419K
FLACU
171
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$756K 0.06%
75,000
– –
SEEL
172
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$739K 0.06%
73
-114
-61% -$1.87M
ICPT
173
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$700K 0.06%
35,000
– –
KRRO icon
174
Korro Bio
KRRO
$145M
$696K 0.06%
1,398
+268
+24% +$131K
CCCC icon
175
C4 Therapeutics
CCCC
$389M
$666K 0.05%
17,600
-93,900
-84% -$3.36M
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.